Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Update on the treatment of Behçet's syndrome.

Esatoglu SN, Hatemi G.

Intern Emerg Med. 2019 Jan 25. doi: 10.1007/s11739-019-02035-1. [Epub ahead of print]

PMID:
30684097
2.

One year in review 2018: Behçet's syndrome.

Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V.

Clin Exp Rheumatol. 2018 Nov-Dec;36(6 Suppl 115):13-27. Epub 2018 Dec 13. Review.

3.

Highlights of the 18th International Conference on Behçet's syndrome.

Esatoglu SN, Kutlubay Z, Hatemi G.

Clin Exp Rheumatol. 2018 Nov-Dec;36(6 Suppl 115):3-12. Epub 2018 Dec 13. No abstract available.

4.

Faecal but not serum calprotectin levels look promising in predicting active disease in Behçet's syndrome patients with gastrointestinal involvement.

Esatoglu SN, Hatemi I, Ozguler Y, Hatemi G, Uzun H, Celik AF, Yazici H.

Clin Exp Rheumatol. 2018 Nov-Dec;36(6 Suppl 115):90-96. Epub 2018 Dec 13.

5.

Management of large-vessel vasculitis.

Salvarani C, Hatemi G.

Curr Opin Rheumatol. 2019 Jan;31(1):25-31. doi: 10.1097/BOR.0000000000000561.

PMID:
30461542
6.

Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations.

Ozguler Y, Leccese P, Christensen R, Esatoglu SN, Bang D, Bodaghi B, Çelik AF, Fortune F, Gaudric J, Gul A, Kötter I, Mahr A, Moots RJ, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H, Hatemi G.

Rheumatology (Oxford). 2018 Dec 1;57(12):2200-2212. doi: 10.1093/rheumatology/key242.

PMID:
30107448
7.

Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome.

Leccese P, Ozguler Y, Christensen R, Esatoglu SN, Bang D, Bodaghi B, Celik AF, Fortune F, Gaudric J, Gül A, Kötter I, Mahr A, Moots RJ, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H, Hatemi G.

Semin Arthritis Rheum. 2018 May 19. pii: S0049-0172(18)30240-3. doi: 10.1016/j.semarthrit.2018.05.008. [Epub ahead of print]

PMID:
29954598
8.

Assessing the possible association of anti-TNF use with new malignancies: A neglected methodological consideration.

Ozguler Y, Yazici Y, Hatemi G, Tascilar K, Yazici H.

Pharmacoepidemiol Drug Saf. 2018 Aug;27(8):894-901. doi: 10.1002/pds.4579. Epub 2018 Jun 19. No abstract available.

PMID:
29920843
9.

Tapering tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective study.

Hacioglu A, Hatemi G, Esatoglu SN, Hamuryudan V.

Clin Exp Rheumatol. 2018 Apr 19. [Epub ahead of print] No abstract available.

PMID:
29745879
10.

2018 update of the EULAR recommendations for the management of Behçet's syndrome.

Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, Gaudric J, Gul A, Kötter I, Leccese P, Mahr A, Moots R, Ozguler Y, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H.

Ann Rheum Dis. 2018 Jun;77(6):808-818. doi: 10.1136/annrheumdis-2018-213225. Epub 2018 Apr 6.

PMID:
29625968
11.

Considerations in designing and interpreting prevalence studies for Behçet syndrome.

Hatemi G, Esatoglu SN, Yurdakul S.

Pol Arch Intern Med. 2018 Mar 29;128(3):148-149. doi: 10.20452/pamw.4233. Epub 2018 Mar 29. No abstract available.

12.

Behçet syndrome: a contemporary view.

Yazici H, Seyahi E, Hatemi G, Yazici Y.

Nat Rev Rheumatol. 2018 Jan 24;14(2):119. doi: 10.1038/nrrheum.2018.3.

PMID:
29362466
13.

Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies.

Ayan G, Esatoglu SN, Hatemi G, Ugurlu S, Seyahi E, Melikoglu M, Fresko I, Ozdogan H, Yurdakul S, Hamuryudan V.

Rheumatol Int. 2018 Apr;38(4):607-622. doi: 10.1007/s00296-018-3928-1. Epub 2018 Jan 10. Review.

PMID:
29322343
14.

Behçet syndrome: a contemporary view.

Yazici H, Seyahi E, Hatemi G, Yazici Y.

Nat Rev Rheumatol. 2018 Feb;14(2):107-119. doi: 10.1038/nrrheum.2017.208. Epub 2018 Jan 3. Review. Erratum in: Nat Rev Rheumatol. 2018 Jan 24;14 (2):119.

PMID:
29296024
15.

Method.

Hatemi G.

Turk J Gastroenterol. 2017 Dec;28(Suppl 1):S3. doi: 10.5152/tjg.2017.02. No abstract available.

16.

Gastrointestinal Involvement in Behçet Disease.

Hatemi I, Hatemi G, Çelik AF.

Rheum Dis Clin North Am. 2018 Feb;44(1):45-64. doi: 10.1016/j.rdc.2017.09.007. Review.

PMID:
29149927
17.

Infliximab for uveitis of Behçet's syndrome: a trend for earlier initiation.

Guzelant G, Ucar D, Esatoglu SN, Hatemi G, Ozyazgan Y, Yurdakul S, Seyahi E, Yazici H, Hamuryudan V.

Clin Exp Rheumatol. 2017 Nov-Dec;35 Suppl 108(6):86-89. Epub 2017 Oct 24.

18.

One year in review 2017: Behçet's syndrome.

Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V.

Clin Exp Rheumatol. 2017 Nov-Dec;35 Suppl 108(6):3-15. Epub 2017 Sep 29. Review.

19.

Biomarkers in vasculitis.

Hatemi G, Esatoglu SN, Yazici Y.

Curr Opin Rheumatol. 2018 Jan;30(1):30-35. doi: 10.1097/BOR.0000000000000447. Review.

PMID:
28937415
20.

Behçet's syndrome: providing integrated care.

Esatoglu SN, Kutlubay Z, Ucar D, Hatemi I, Uygunoglu U, Siva A, Hatemi G.

J Multidiscip Healthc. 2017 Aug 14;10:309-319. doi: 10.2147/JMDH.S93681. eCollection 2017. Review.

21.

Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study.

Esatoglu SN, Hatemi G, Ugurlu S, Gokturk A, Tascilar K, Ozdogan H.

Medicine (Baltimore). 2017 Aug;96(34):e7859. doi: 10.1097/MD.0000000000007859.

22.

Developing a Core Set of Outcome Measures for Behçet Disease: Report from OMERACT 2016.

Hatemi G, Meara A, Ozguler Y, Direskeneli H, Mahr A, Easley E, Gurcan M, Davis T, Gul A, Yazici Y, Zottenberg K, Esatoglu SN, Erer B, Kamali S, Yazici H, Cronholm PF, Merkel PA.

J Rheumatol. 2017 Nov;44(11):1750-1753. doi: 10.3899/jrheum.161352. Epub 2017 Apr 1.

PMID:
28365574
23.

Highlights of the 17th International Conference on Behçet's syndrome.

Esatoglu SN, Hatemi G, Leccese P, Olivieri I.

Clin Exp Rheumatol. 2016 Sep-Oct;34(6 Suppl 102):3-9. Epub 2016 Oct 25. No abstract available.

24.

One year in review 2016: Behçet's syndrome.

Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V.

Clin Exp Rheumatol. 2016 Sep-Oct;34(6 Suppl 102):10-22. Epub 2016 Oct 13. Review.

25.

Behçet's disease: an MHC-I-opathy?

Hatemi G, Karatemiz G, Yazici H.

Clin Exp Rheumatol. 2017 May-Jun;35 Suppl 104(2):5. Epub 2016 Oct 24. No abstract available.

26.

Inadequate reporting of enrolled patient and study site characteristics, and inter-study site differences in randomized controlled trials: A systematic review in six leading medicine journals.

Yurdakul S, Ayan G, Ozguler Y, Hatemi G, Ugurlu S, Seyahi E, Yazici H.

Eur J Intern Med. 2017 Jan;37:e34-e36. doi: 10.1016/j.ejim.2016.09.019. Epub 2016 Oct 5. Review. No abstract available.

PMID:
27720299
27.

Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy.

Ozguler Y, Hatemi G, Ugurlu S, Seyahi E, Melikoglu M, Borekci S, Atahan E, Ongen G, Hamuryudan V.

Rheumatol Int. 2016 Dec;36(12):1719-1725. Epub 2016 Oct 3.

PMID:
27699578
28.

Systemic vasculitis and the gut.

Hatemi I, Hatemi G, Çelik AF.

Curr Opin Rheumatol. 2017 Jan;29(1):33-38. Review.

PMID:
27684357
29.

Characteristics, Treatment, and Long-Term Outcome of Gastrointestinal Involvement in Behcet's Syndrome: A Strobe-Compliant Observational Study From a Dedicated Multidisciplinary Center.

Hatemi I, Esatoglu SN, Hatemi G, Erzin Y, Yazici H, Celik AF.

Medicine (Baltimore). 2016 Apr;95(16):e3348. doi: 10.1097/MD.0000000000003348.

32.

Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-α Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence.

Kisacik B, Pamuk ON, Onat AM, Erer SB, Hatemi G, Ozguler Y, Pehlivan Y, Kilic L, Ertenli I, Can M, Direskeneli H, Keser G, Oksel F, Dalkilic E, Yilmaz S, Pay S, Balkarli A, Cobankara V, Cetin GY, Sayarlioglu M, Cefle A, Yazici A, Avci AB, Terzioglu E, Ozbek S, Akar S, Gul A.

J Rheumatol. 2016 Mar;43(3):524-9. doi: 10.3899/jrheum.150177. Epub 2016 Jan 15.

PMID:
26773107
33.

Management of Behçet's syndrome.

Ozguler Y, Hatemi G.

Curr Opin Rheumatol. 2016 Jan;28(1):45-50. doi: 10.1097/BOR.0000000000000231. Review.

PMID:
26555450
34.

Behçet's syndrome: a critical digest of the 2014-2015 literature.

Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V.

Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S3-14. Epub 2015 Oct 19. Review.

PMID:
26487500
35.

Fatigue is correlated with disease activity but not with the type of organ involvement in Behçet's syndrome: a comparative clinical survey.

Buyuktas D, Hatemi G, Yuksel-Findikoglu S, Ugurlu S, Yazici H, Yurdakul S.

Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S107-12. Epub 2015 Oct 19.

PMID:
26487169
36.

TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature.

Hatemi I, Hatemi G, Pamuk ON, Erzin Y, Celik AF.

Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S129-37. Epub 2015 Oct 20. Review.

PMID:
26486925
37.

Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014.

Hatemi G, Ozguler Y, Direskeneli H, Mahr A, Gul A, Levi V, Aydin SZ, Mumcu G, Sertel-Berk O, Stevens RM, Yazici H, Merkel PA.

J Rheumatol. 2015 Dec;42(12):2436-41. doi: 10.3899/jrheum.141147. Epub 2015 Sep 15. Review.

38.

Diagnostic Criteria as Separate From Classification Criteria: A Perpetual Motion Machine? Comment on the Article by Aggarwal et al.

Yazici H, Hatemi G, Yazici Y.

Arthritis Care Res (Hoboken). 2016 Jul;68(7):1049. doi: 10.1002/acr.22718. No abstract available.

39.

Pulmonary artery involvement in Behçet׳s syndrome: Effects of anti-Tnf treatment.

Hamuryudan V, Seyahi E, Ugurlu S, Melikoglu M, Hatemi G, Ozguler Y, Akman C, Tuzun H, Yurdakul S, Yazici H.

Semin Arthritis Rheum. 2015 Dec;45(3):369-73. doi: 10.1016/j.semarthrit.2015.06.008. Epub 2015 Jun 18.

PMID:
26190564
40.

Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12.

Aydin SZ, Direskeneli H, Sreih A, Alibaz-Oner F, Gul A, Kamali S, Hatemi G, Kermani T, Mackie SL, Mahr A, Meara A, Milman N, Nugent H, Robson J, Tomasson G, Merkel PA.

J Rheumatol. 2015 Dec;42(12):2465-9. doi: 10.3899/jrheum.141144. Epub 2015 Jun 15. Review.

41.

Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.

Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Turgut Ozturk B, Mat C, Merkel PA, Calamia KT, Liu Z, Pineda L, Stevens RM, Yazici H, Yazici Y.

N Engl J Med. 2015 Apr 16;372(16):1510-8. doi: 10.1056/NEJMoa1408684.

42.

Development of eosinophilic granulomatosis with poliangiitis (Churg-Strauss syndrome) and brain tumor in a patient after more than 7 years of omalizumab use: A case report.

Borekci S, Aydin O, Hatemi G, Gemicioglu B.

Int J Immunopathol Pharmacol. 2015 Mar;28(1):134-7. doi: 10.1177/0394632015572567.

PMID:
25816417
43.

Suicidal ideation among patients with Behçet's syndrome.

Saygin C, Uzunaslan D, Hatemi G, Hamuryudan V.

Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S30-5. Epub 2015 Mar 23.

PMID:
25797433
44.

Currently Used Biologic Agents in the Management of Behcet's Syndrome.

Saygin C, Uzunaslan D, Hatemi G.

Curr Med Chem. 2015;22(16):1976-85. Review.

PMID:
25666786
45.

A reappraisal of the association between Behçet's disease, myelodysplastic syndrome and the presence of trisomy 8: a systematic literature review.

Esatoglu SN, Hatemi G, Salihoglu A, Hatemi I, Soysal T, Celik AF.

Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S145-51. Epub 2015 Feb 9. Review.

PMID:
25664843
46.

Double pylorus in a patient with Behçet's syndrome.

Hatemi I, Hatemi G, Erzin YZ, Celik AF.

Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S138-40. Epub 2015 Feb 9.

PMID:
25664680
47.

Biologics, colchicine, corticosteroids, immunosuppressants and interferon-alpha for Neuro-Behçet's Syndrome.

Nava F, Ghilotti F, Maggi L, Hatemi G, Del Bianco A, Merlo C, Filippini G, Tramacere I.

Cochrane Database Syst Rev. 2014;(12):CD010729. doi: 10.1002/14651858.CD010729.pub2. Epub 2014 Dec 18. Review.

PMID:
25521793
48.

Behçet's syndrome: a critical digest of the 2013-2014 literature.

Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V.

Clin Exp Rheumatol. 2014 Jul-Aug;32(4 Suppl 84):S112-22. Epub 2014 Sep 30. Review.

PMID:
25268667
49.

Mentoring of young professionals in the field of rheumatology in Europe: results from an EMerging EUlar NETwork (EMEUNET) survey.

Frank-Bertoncelj M, Hatemi G, Ospelt C, Ramiro S, Machado P, Mandl P, Gossec L, Buch MH.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6):935-41. Epub 2014 Sep 8.

PMID:
25198292
50.

Turkish PASE: Turkish Version of the Psoriatic Arthritis Screening and Evaluation Questionnaire.

Oyur KB, Engin B, Hatemi G, Asma A, Kutlubay Z, Bulut N, Serdaroğlu S, Tüzün Y.

Ann Dermatol. 2014 Aug;26(4):457-61. doi: 10.5021/ad.2014.26.4.457. Epub 2014 Jul 31.

Supplemental Content

Loading ...
Support Center